Shattuck Labs

$5.20 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Shattuck Labs

Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of dual-sided fusion proteins. The Company has created an approach to immune modulation by designing biologics with structural characteristics. Compounds derived from its Agonist Redirected Checkpoint (ARC) platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the cluster of differentiation 47/signal regulatory protein alpha (CD47/SIRPa) checkpoint interaction to restore an anti-tumor immune response and to activate the cluster of differentiation 40 (CD40) costimulatory receptor to bolster an immune response. The Company's second product candidate, SL-279252, is designed to simultaneously inhibit the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) interaction and activate the OX40 receptor.

Stock Analysis

last close $5.2
1-mo return 61.5%
3-mo return 29%
avg daily vol. 377.52T
52-week high 27.15
52-week low 2.59
market cap. $186M
forward pe -
annual div. -
roe -21.1%
ltg forecast -
dividend yield -
annual rev. $28M
inst own. 57.4%

Subscribe now for daily local and international financial news